Harrow
Amir Shojaei currently serves as the Chief Scientific Officer at Harrow since January 2025 and as a Board Member at iVeena. Previously, Amir held significant roles including Executive Board Member at ForwardVue Pharma, Chief Scientific Officer and EVP-Clinical Development at AsclepiX Therapeutics, CEO at TherOptix, and Chief Development Officer at TearClear. Amir's expertise in ophthalmology includes leadership roles at Novartis and Takeda, as well as a longstanding tenure at Shire in global clinical development. Amir co-founded SIDE Pharmaceuticals, LLC, and possesses advanced degrees in Pharmaceutical Sciences and Pharmacy from the University of the Pacific, along with a Bachelor of Science in Biological Sciences from the University of Alberta.
This person is not in any teams
This person is not in any offices
Harrow
2 followers
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.